VistaGen signs licensing deal for stem cell culture technology

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

Singapore Seeking Pharmaceutical Tariff Concessions from US

The deputy prime minister and trade minister of Singapore,...

Merck to Acquire Verona for $10B, COPD Drug in Focus

Merck has pulled off another acquisition that happens to...

PDUFA Crucial for Biopharmaceutical Innovation in the US

The United States happens to lead the world when...

The Evolution of Self-Care: Where Vitauthority Fits in the Wellness Era

Over the past few decades, the concept of self-care...

VistaGen Therapeutics has signed a licensing agreement with the McEwen Centre for Regenerative Medicine located at the University Health Network in Toronto, Canada, for stem cell culture technology.

VistaGen will utilize the licensed technology to develop hematopoietic precursor stem cells from human pluripotent stem cells, to develop drug screening and cell therapy applications for human blood system disorders.

Hematopoietic precursor stem cells give rise to all red and white blood cells and platelets in the body. VistaGen will use the technology to improve the cell culture methods used to produce hematopoietic stem cell populations.

VistaGen president and chief scientific officer Ralph Snodgrass said: “This technology dramatically advances our ability to produce and purify this important blood stem cell precursor for both in vitro drug screening and in vivo cell therapy applications.”

Latest stories

Related stories

Singapore Seeking Pharmaceutical Tariff Concessions from US

The deputy prime minister and trade minister of Singapore,...

Merck to Acquire Verona for $10B, COPD Drug in Focus

Merck has pulled off another acquisition that happens to...

PDUFA Crucial for Biopharmaceutical Innovation in the US

The United States happens to lead the world when...

The Evolution of Self-Care: Where Vitauthority Fits in the Wellness Era

Over the past few decades, the concept of self-care...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back